The CAFC’s Amgen v Sanofi decision spells trouble for broad functional patent claims

The CAFC’s much-anticipated ruling has major implications for antibody patents and continues the court’s trend of imposing a tough enablement standard for genus claims


Get unlimited access to all IAM content